Global Comprehensive Metabolic Panel Testing Market Size Study & Forecast, by Test Type (Glucose, Calcium, Electrolytes, Kidney Function Tests, Liver Function Tests, Proteins), By Disease Indication (Kidney Diseases, Liver Diseases, Diabetes, Other Diseas

Global Comprehensive Metabolic Panel Testing Market Size Study & Forecast, by Test Type (Glucose, Calcium, Electrolytes, Kidney Function Tests, Liver Function Tests, Proteins), By Disease Indication (Kidney Diseases, Liver Diseases, Diabetes, Other Disease Indications), By End-Use (Point Of Care Centers, Diagnostic Laboratories, Hospitals, Other End-Users), and Regional Analysis, 2023-2030

Global Comprehensive Metabolic Panel Testing Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Comprehensive Metabolic Panel Testing assesses 14 distinct substances within your bloodstream, offering valuable insights into the body's chemical equilibrium and metabolic processes (the conversion of food into energy). CMPs are commonly employed by healthcare professionals for routine blood analysis and as a tool to aid in the diagnosis, screening, or ongoing monitoring of specific health conditions. The demand for CMP testing is projected to surge due to factors such as the growing emphasis on early diagnosis and treatment of chronic disease, the growing aging population, proactive government measures and healthcare policies, and investments in healthcare infrastructure development and expansion of healthcare facilities.

The increasing prevalence of chronic diseases such as diabetes, kidney disease, and liver disease are major drivers for the growth of the CMP Testing Market. The elevated prevalence of lifestyle-related conditions, including obesity, smoking, poor dietary choices, and sedentary lifestyles, contributes to the escalating rates of chronic diseases. These diseases require regular monitoring of the patient's metabolic processes. For instance, as per the International Diabetic Federation (IDF), in 2019, there were nearly 463 million adults aged between 20-79 years suffering from diabetes. Also, the amount is anticipated to reach around 700 million by 2045. Thus, the rise in the prevalence of diabetes acts as a key driving factor, which, in turn, propels the growth of the Comprehensive Metabolic Panel Testing Market during the estimated period. Moreover, the technological advancements in comprehensive metabolic panel testing, as well as rising inclination towards the usage of point-of-care devices present various lucrative opportunities over the forecast years. However, the lack of reimbursement scenario and stringent regulatory scenario are challenging the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Comprehensive Metabolic Panel Testing Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the rising prevalence of diseases, increased public awareness, proactive government initiatives, technological advancements, and enhancements in healthcare facilities. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecast years. This growth is fueled by several factors, including enhancements in healthcare infrastructure, an increasing elderly population susceptible to chronic illnesses, heightened public awareness, a boost in disposable income, and overall economic advancement. According to data from the Asian Development Bank, the Asia-Pacific region is projected to see one in four individuals surpassing the age of 60 by 2050, with the elderly population in the region expected to quadruple between 2010 and 2050. Accordingly, emerging countries such as China, India, and South Korea are anticipated to experience rapid growth in demand for CMP testing within the forecast period.

Major market players included in this report are:
Abbott Laboratories
Quest Diagnostics
Laboratory Corporation of America Holdings
Sonic Healthcare Limited
Unipath
SYNLAB International GmbH
ARUP Laboratories
Genoptix Inc.
Nova Medical
Charles River Laboratories Inc.

Recent Developments in the Market:
 In April 2020, Nova Biomedical received FDA approval for their Stat Profile Prime Plus critical care blood gas analyzer, allowing it to be used directly at the Point of Care (POC). This advanced analyzer conducts 19 vital critical care tests, encompassing blood gases, metabolites, electrolytes, hematology, and co-oximetry, all of which are sensor tests that require no ongoing maintenance. This technology empowers healthcare professionals to swiftly obtain a comprehensive diagnostic profile, including a complete metabolic panel.
 In August 2020, The GEM Premier family has unveiled the GEM Premier ChemSTAT system, a whole-blood analyzer developed for swift basic metabolic panel (BMP) testing at the point of care. Primarily designed for efficiency in hospital emergency departments (EDs) and clinical laboratories, this system addresses the need for rapid and accurate testing in these critical healthcare settings..

Global Comprehensive Metabolic Panel Testing Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Test Type, Disease Indication, End-use, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Test Type:
Glucose
Calcium
Electrolytes
Kidney function tests
Liver function tests
Proteins

By Disease Indication:
Kidney diseases
Liver diseases
Diabetes
Other disease indications

By End-use:
Point of care centers
Diagnostic laboratories
Hospitals
Other end-users

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa


Companies Mentioned
Abbott Laboratories
Quest Diagnostics
Laboratory Corporation of America Holdings
Sonic Healthcare Limited
Unipath
SYNLAB International GmbH
ARUP Laboratories
Genoptix Inc.
Nova Medical
Charles River Laboratories Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.